Metal nanoparticles for the treatment and diagnosis of neurodegenerative brain diseases

Valentina Vio, Maria José Marchant, Eyleen Araya, Marcelo J. Kogan

Resultado de la investigación: Research - revisión exhaustivaReview article

Resumen

This review focuses on the application of metal nanoparticles in the diagnosis and treatment of Alzheimer’s and Parkinson’s diseases. Metal nanoparticles present interesting physicochemical properties that can be applied to increase biomarker detection sensitivities in vitro and in vivo. Furthermore, these nanoparticles could be used in different strategies for the treatment of central nervous system diseases, particularly in regards to drug delivery. Herein, specific potential applications of metal nanoparticles are separately discussed for the contexts of in vitro diagnoses and treatments. Briefly, research using surface plasmon resonance methodologies has mainly used these nanoparticles for the in vitro detection of Aβ and, to a lesser extent, of α-synuclein. Regarding treatment approaches, in vitro studies have focused on using metal nanoparticles to manipulate the Aβ aggregation, thus reducing toxicity. Furthermore, in vivo applications of metal nanoparticles are also discussed, with many of the existing studies focusing on a magnetic nanoparticle-detection of Aβ through magnetic resonance imaging and, to a lesser degree, extension fluorescence techniques. Finally, conclusions and perspectives are provided regarding the real potential for using metal nanoparticles in the treatment and diagnosis of central nervous system diseases.

IdiomaEnglish
Páginas1916-1926
Número de páginas11
PublicaciónCurrent Pharmaceutical Design
Volumen23
Número de edición13
DOI
EstadoPublished - 1 abr 2017

Huella dactilar

Metal Nanoparticles
Brain Diseases
Neurodegenerative Diseases
In Vitro Techniques
Nanoparticles
Central Nervous System Diseases
alpha-Synuclein
Surface Plasmon Resonance
Parkinson Disease
Biomarkers
Fluorescence
Magnetic Resonance Imaging
Research
Pharmaceutical Preparations

Keywords

    ASJC Scopus subject areas

    • Pharmacology
    • Drug Discovery

    Citar esto

    Vio, Valentina ; Marchant, Maria José ; Araya, Eyleen ; Kogan, Marcelo J./ Metal nanoparticles for the treatment and diagnosis of neurodegenerative brain diseases. En: Current Pharmaceutical Design. 2017 ; Vol. 23, N.º 13. pp. 1916-1926
    @article{67cf21d09f0f41cd981e7a76eded7db5,
    title = "Metal nanoparticles for the treatment and diagnosis of neurodegenerative brain diseases",
    abstract = "This review focuses on the application of metal nanoparticles in the diagnosis and treatment of Alzheimer’s and Parkinson’s diseases. Metal nanoparticles present interesting physicochemical properties that can be applied to increase biomarker detection sensitivities in vitro and in vivo. Furthermore, these nanoparticles could be used in different strategies for the treatment of central nervous system diseases, particularly in regards to drug delivery. Herein, specific potential applications of metal nanoparticles are separately discussed for the contexts of in vitro diagnoses and treatments. Briefly, research using surface plasmon resonance methodologies has mainly used these nanoparticles for the in vitro detection of Aβ and, to a lesser extent, of α-synuclein. Regarding treatment approaches, in vitro studies have focused on using metal nanoparticles to manipulate the Aβ aggregation, thus reducing toxicity. Furthermore, in vivo applications of metal nanoparticles are also discussed, with many of the existing studies focusing on a magnetic nanoparticle-detection of Aβ through magnetic resonance imaging and, to a lesser degree, extension fluorescence techniques. Finally, conclusions and perspectives are provided regarding the real potential for using metal nanoparticles in the treatment and diagnosis of central nervous system diseases.",
    keywords = "Drug delivery, Imaging, Nanoparticle-detection, Neurodegenerative disorders, Physicochemical properties, Theranostic",
    author = "Valentina Vio and Marchant, {Maria José} and Eyleen Araya and Kogan, {Marcelo J.}",
    year = "2017",
    month = "4",
    doi = "10.2174/1381612823666170105152948",
    volume = "23",
    pages = "1916--1926",
    journal = "Current Pharmaceutical Design",
    issn = "1381-6128",
    publisher = "Bentham Science Publishers B.V.",
    number = "13",

    }

    Metal nanoparticles for the treatment and diagnosis of neurodegenerative brain diseases. / Vio, Valentina; Marchant, Maria José; Araya, Eyleen; Kogan, Marcelo J.

    En: Current Pharmaceutical Design, Vol. 23, N.º 13, 01.04.2017, p. 1916-1926.

    Resultado de la investigación: Research - revisión exhaustivaReview article

    TY - JOUR

    T1 - Metal nanoparticles for the treatment and diagnosis of neurodegenerative brain diseases

    AU - Vio,Valentina

    AU - Marchant,Maria José

    AU - Araya,Eyleen

    AU - Kogan,Marcelo J.

    PY - 2017/4/1

    Y1 - 2017/4/1

    N2 - This review focuses on the application of metal nanoparticles in the diagnosis and treatment of Alzheimer’s and Parkinson’s diseases. Metal nanoparticles present interesting physicochemical properties that can be applied to increase biomarker detection sensitivities in vitro and in vivo. Furthermore, these nanoparticles could be used in different strategies for the treatment of central nervous system diseases, particularly in regards to drug delivery. Herein, specific potential applications of metal nanoparticles are separately discussed for the contexts of in vitro diagnoses and treatments. Briefly, research using surface plasmon resonance methodologies has mainly used these nanoparticles for the in vitro detection of Aβ and, to a lesser extent, of α-synuclein. Regarding treatment approaches, in vitro studies have focused on using metal nanoparticles to manipulate the Aβ aggregation, thus reducing toxicity. Furthermore, in vivo applications of metal nanoparticles are also discussed, with many of the existing studies focusing on a magnetic nanoparticle-detection of Aβ through magnetic resonance imaging and, to a lesser degree, extension fluorescence techniques. Finally, conclusions and perspectives are provided regarding the real potential for using metal nanoparticles in the treatment and diagnosis of central nervous system diseases.

    AB - This review focuses on the application of metal nanoparticles in the diagnosis and treatment of Alzheimer’s and Parkinson’s diseases. Metal nanoparticles present interesting physicochemical properties that can be applied to increase biomarker detection sensitivities in vitro and in vivo. Furthermore, these nanoparticles could be used in different strategies for the treatment of central nervous system diseases, particularly in regards to drug delivery. Herein, specific potential applications of metal nanoparticles are separately discussed for the contexts of in vitro diagnoses and treatments. Briefly, research using surface plasmon resonance methodologies has mainly used these nanoparticles for the in vitro detection of Aβ and, to a lesser extent, of α-synuclein. Regarding treatment approaches, in vitro studies have focused on using metal nanoparticles to manipulate the Aβ aggregation, thus reducing toxicity. Furthermore, in vivo applications of metal nanoparticles are also discussed, with many of the existing studies focusing on a magnetic nanoparticle-detection of Aβ through magnetic resonance imaging and, to a lesser degree, extension fluorescence techniques. Finally, conclusions and perspectives are provided regarding the real potential for using metal nanoparticles in the treatment and diagnosis of central nervous system diseases.

    KW - Drug delivery

    KW - Imaging

    KW - Nanoparticle-detection

    KW - Neurodegenerative disorders

    KW - Physicochemical properties

    KW - Theranostic

    UR - http://www.scopus.com/inward/record.url?scp=85021271996&partnerID=8YFLogxK

    U2 - 10.2174/1381612823666170105152948

    DO - 10.2174/1381612823666170105152948

    M3 - Review article

    VL - 23

    SP - 1916

    EP - 1926

    JO - Current Pharmaceutical Design

    T2 - Current Pharmaceutical Design

    JF - Current Pharmaceutical Design

    SN - 1381-6128

    IS - 13

    ER -